Does TOFACITINIB Cause Low density lipoprotein increased? 135 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 135 reports of Low density lipoprotein increased have been filed in association with TOFACITINIB (XELJANZ XR). This represents 0.1% of all adverse event reports for TOFACITINIB.
135
Reports of Low density lipoprotein increased with TOFACITINIB
0.1%
of all TOFACITINIB reports
0
Deaths
6
Hospitalizations
How Dangerous Is Low density lipoprotein increased From TOFACITINIB?
Of the 135 reports, 6 (4.4%) required hospitalization, and 1 (0.7%) were considered life-threatening.
Is Low density lipoprotein increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 135 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Low density lipoprotein increased?
EVOLOCUMAB (1,024)
INCLISIRAN (423)
ALIROCUMAB (336)
ROSUVASTATIN (241)
ATORVASTATIN (217)
EZETIMIBE (217)
LOMITAPIDE (164)
FINGOLIMOD (132)
SOMATROPIN (93)
LORLATINIB (78)
Which TOFACITINIB Alternatives Have Lower Low density lipoprotein increased Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN